10x Genomics, Inc. (TXG)

↓ Download CSV

CIK 0001770787 · Nasdaq · Laboratory Analytical Instruments

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, 10x Genomics, Inc. reported revenue of $642.82M, up 5.2% from the prior year. The company ran a net loss, with a net margin of -6.8% and a gross margin of 69.1%. It held $1.04B in total assets against $245.04M in total liabilities.

Key ratios (FY2025)

69.1%
Gross margin
-9.5%
Operating margin
-6.8%
Net margin
-5.5%
Return on equity
+5.2%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$642.82M$610.78M$618.73M$516.41M$490.49M$298.85M$245.89M$146.31M
Cost of Revenue$198.94M$196.30M$209.41M$120.39M$74.09M$58.47M$61.03M$28.66M$10.56M
Gross Profit$443.88M$414.48M$409.31M$396.02M$416.40M$240.38M$184.86M$117.65M$60.52M
Operating Income-$60.98M-$194.56M-$265.33M-$167.94M-$52.25M-$534.14M-$30.57M-$110.76M-$18.38M
Net Income-$43.54M-$182.63M-$255.10M-$166.00M-$58.22M-$542.73M-$31.25M-$112.48M-$18.76M
EPS (Diluted)$-0.35$-1.52$-2.18$-1.46$-0.53$-5.37$-0.80
Total Assets$1.04B$918.64M$965.14M$1.03B$1.02B$929.34M$605.92M$124.31M
Total Liabilities$245.04M$208.50M$224.10M$223.24M$201.26M$190.27M$185.84M$101.05M
Shareholders' Equity$796.33M$710.13M$741.04M$805.74M$817.57M$739.07M$420.08M-$219.99M-$112.51M-$96.43M
Cash & Equivalents$344.07M$359.28M$219.75M$587.45M$663.60M$424.17M$65.08M$47.86M
Operating Cash Flow$136.05M$6.66M-$15.20M-$33.61M-$21.37M-$217.90M$34.63M-$76.41M-$10.70M
Capital Expenditures$5.93M$12.39M$48.60M$131.66M$101.28M$36.67M$42.74M$6.28M$3.76M
Shares Outstanding127.69M122.29M119.10M115.20M112.51M108.49M96.24M14.55M